Target and Translate Treg Modifying Therapies with Enhanced Persistence and Durability to Address Unmet Medical Need Safely, Effectively and at Scale (1)

The 3rd Treg Directed Therapies Summit wass the industry-led meeting focused on targeting and translating Treg modifying therapies with enhanced persistence and durability safely and at scale.

This exclusive community joined online to virtually network and learn from the leading experts in pharma, biotech and academia, to discuss how to robustly modify the Treg response through novel gene engineering and ensure scale and efficiency of cell sorting and isolation for effective cell expansion.

3 days of content explored how to optimize and bring to clinic Treg directed therapies to address huge unmet medical need in autoimmune, allergic, transplant, inflammatory indications. Download the 2021 event guide to learn more.

2021 Expert Speakers Included:

Adel Nada

Co-Founder, President, CEO

GentiBio

Jérémie Mariau

CEO

ILTOO PHARMA

Jo Viney

Co-Founder, President & CSO

Pandion Therapeutics

Marc Martinez- Llordella

co-Founder & VP Biology, Visiting Lecturer

Quell Therapeutics, King’s College London

Wayne Hancock

Professor of Pathology & Laboratory Medicine and Chief of the Division of Transplant Immunology

Children’s Hospital of Philadelphia and University of Pennsylvania School of Medicine

Proud To Partner With:

Sangamo-logo-300x158
Adaptative
Logo1_WB_PNG
Akron Biotech Logo.png
Harvard logo